Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) shares fell 3.5% during mid-day trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares traded hands during trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Trading Down 3.5 %
The business’s 50 day moving average is C$16.76. The firm has a market capitalization of C$2.15 billion and a P/E ratio of -11.32. The company has a debt-to-equity ratio of 2.69, a quick ratio of 11.02 and a current ratio of 11.93.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Recommended Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Golden Cross Stocks: Pattern, Examples and Charts
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Find and Profitably Trade Stocks at 52-Week Lows
- 2 Option Strategies to Maximize Profits in a Bear Market
- Investing in Travel Stocks Benefits
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
